HIV drug dosing study aims to protect moms and babies
NCT ID NCT05630638
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how the HIV drug doravirine works in pregnant women. Researchers want to find the right dose to keep the virus under control and protect the baby. About 76 pregnant women with HIV will take either doravirine or standard HIV medication starting in the second trimester. The study will measure drug levels in the blood, breastmilk, and cord blood to ensure safety and effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Doravirine (with lamivudine and tenofovir disoproxil)
What this could lead to
If successful, this could help establish safe and effective doravirine dosing for pregnant women with HIV, improving treatment options during pregnancy.
What could go wrong
This is a small, early-phase pharmacokinetic study, not designed to prove long-term outcomes. Results may not apply to all populations, and there are unknown risks to the baby.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Desmond Tutu Health Foundation
RECRUITINGCape Town, South Africa
Contact Email: •••••@•••••
Contact
Contact